Acquisition enhances Scantox's genomics capabilities and service offerings.
- Scantox acquires DuplexSeq to enhance genomics capabilities.
- The acquisition strengthens nonclinical safety services.
- DuplexSeq specializes in advanced genomic solutions.
Scantox has acquired the DuplexSeq nonclinical genomics safety business from Twinstrand Biosciences. This acquisition aims to strengthen Scantox's capabilities in providing genomic services focused on nonclinical safety. With this move, Scantox seeks to enhance its service offerings in the rapidly evolving field of genomics.
DuplexSeq is recognized for its advanced genomic solutions, and this integration is expected to amplify Scantox's existing service portfolio. The addition of DuplexSeq's expertise will enable Scantox to better serve its clientele by incorporating cutting-edge genomic insights into their safety assessments. This strategic acquisition highlights Scantox's commitment to delivering comprehensive solutions in the realm of nonclinical genomics.
By acquiring DuplexSeq, Scantox plans to leverage these new capabilities to improve its analytical processes and ultimately offer enhanced safety evaluations. This development marks a significant step forward for the company as it continues to grow in the field of genomics and reinforces its role in advancing safety standards.
